[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334920-105":59,"doc-detail-334920-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","parp-ish-gaps-in-molecular-understanding-and-clinical-trials-targeting-parp-exacerbate-racial-disparities-in-prostate-cancer","PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer","","PARP is a nuclear enzyme central to the DNA damage response, and PARP inhibitors (PARPi) are used for advanced prostate tumors with homologous recombination repair defects. Multiple PARPi are approved and others remain in clinical trials, yet trial efficacy can differ by the specific PARPi and by patient race. Prostate cancer shows marked racial disparities: African American men face higher incidence and mortality than European American men, while clinical trial cohorts lack sufficient diversity. This review examines PARP nuclear functions, inhibition, and clinical implications through racial differences, integrating explored biological variations to support studying PARPi response across basic science and clinical development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parp-ish-gaps-in-molecular-understanding-and-clinical-trials-targeting-parp-exacerbate-racial-disparities-in-prostate-cancer/334920/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parp-ish-gaps-in-molecular-understanding-and-clinical-trials-targeting-parp-exacerbate-racial-disparities-in-prostate-cancer/334920.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does PARP play in prostate cancer biology?","Question",{"text":112,"@type":113},"PARP is a nuclear enzyme with a major function in the DNA damage response. This biology underpins why PARP inhibitors can be effective in tumors with homologous recombination repair defects.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do clinical trial results for PARP inhibitors relate to patient race?",{"text":117,"@type":113},"Reported clinical trial outcomes show differential efficacy depending on which PARP inhibitor is used and on patient race. The review highlights racial differences as an important lens for interpreting PARPi response.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment-related disparities exist between African American and European American men?",{"text":121,"@type":113},"Compared with European American men, African American men were more likely to receive active surveillance and radiotherapy, and less likely to receive radical prostatectomy. These differences were reported even when disease was more advanced.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334920,1790028218,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer  \nMoriah L. Cunningham1,3 and Matthew J. Schiewer1,2,3  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | PARP is a nuclear enzyme with a major function in the DNA damage response. PARP inhibitors (PARPi) have been developed for treating tumors harboring homologous recombination repair defects that lead to a dependency on PARP. There are currently three PARPi approved for use in advanced prostate cancer, and several others are in clinical trials for this disease. Recent clinical trial results have reported differential efficacy based on the specific PARPi utilized as well as patient race. There is a racial disparity in prostate cancer, in which African American males are twice as likely to develop and die from the\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | disease compared with European American males. Despite the disparity, there continues to be a lack of diversity in clinical trial cohorts for prostate cancer. In this review, PARP nuclear functions, inhibition, and clinical relevance are explored through the lens of racial differences. This review will touch on the biological variations that have been explored thus far between African American and European American males with prostate cancer to offer a rationale for investigating PARPi response in the context of race at both basic science and clinical development levels. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nProstate cancer is the most frequently diagnosed and second most fatal cancer in American men (1, 2) . The American Cancer Society predicts that there will be nearly 300,000 cases and approximately 35,000 deaths due to prostate cancer in the United States in 2024 (1) . African American (AA) men are at the highest risk of developing prostate cancer in their lifetime as well as at the highest risk of dying from the disease (3, 4) . A recent study in 2022 from the Veteran’s Affairs suggested that AA men are diagnosed at a younger age, have a higher Gleason score, exhibit higher PSA expression, and are at a higher risk for prostate cancer than European American (EA) males (5) . In 2007, a study from John Hopkins hypothesized that the difference in PSA in AA men may correlate with prostate size between AA and EA males (6) . Their study found that elevated PSA levels in AA patients compared with EA patients were not correlated with larger prostate size in AA men. There is still no conclusive hypothesis about AA men having higher serum PSA levels compared with EA males (7) . AA men also have two times higher incidence and mortality rates for prostate cancer than EA men (8). Recent data suggest that there may be biological differences between AA and EA tumors (9–12) .  \n1Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania. 2Department of Pharmacol","cbCaitKwm8sM9v8R","https://ap.wps.com/l/cbCaitKwm8sM9v8R","pdf",2205253,11,"English","# Introduction\n## PARP function and PARP inhibitors in advanced prostate cancer\n## Racial disparities in prostate cancer incidence and mortality\n## Evidence for biological differences and trial diversity gaps\n## Clinical management options and treatment disparities","[{\"question\":\"What role does PARP play in prostate cancer biology?\",\"answer\":\"PARP is a nuclear enzyme with a major function in the DNA damage response. This biology underpins why PARP inhibitors can be effective in tumors with homologous recombination repair defects.\"},{\"question\":\"How do clinical trial results for PARP inhibitors relate to patient race?\",\"answer\":\"Reported clinical trial outcomes show differential efficacy depending on which PARP inhibitor is used and on patient race. The review highlights racial differences as an important lens for interpreting PARPi response.\"},{\"question\":\"What treatment-related disparities exist between African American and European American men?\",\"answer\":\"Compared with European American men, African American men were more likely to receive active surveillance and radiotherapy, and less likely to receive radical prostatectomy. These differences were reported even when disease was more advanced.\"}]","PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer | PDF",1790008860,28]